Drug Profile
Autologous T cell therapy - PersImmune
Alternative Names: PACTNLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PersImmune
- Class Antineoplastics; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myelodysplastic syndromes
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in USA (IV, Infusion)
- 01 Dec 2018 Interim adverse events data from a phase-I trial in Myelodysplastic syndromes (Second-line therapy or greater) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
- 01 Jan 2018 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) (NCT03258359)